| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 6113 | 2021 |
| Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America JR Perfect, WE Dismukes, F Dromer, DL Goldman, JR Graybill, RJ Hamill, ... Clinical infectious diseases 50 (3), 291-322, 2010 | 3402 | 2010 |
| Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group … JP Donnelly, SC Chen, CA Kauffman, WJ Steinbach, JW Baddley, ... Clinical Infectious Diseases 71 (6), 1367-1376, 2020 | 2962 | 2020 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2769* | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1486 | 2021 |
| Tackling the emerging threat of antifungal resistance to human health MC Fisher, A Alastruey-Izquierdo, J Berman, T Bicanic, EM Bignell, ... Nature reviews microbiology 20 (9), 557-571, 2022 | 1135 | 2022 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 806* | 2022 |
| Cryptococcal meningitis T Bicanic, TS Harrison British medical bulletin 72 (1), 99-118, 2004 | 675 | 2004 |
| Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial AE Brouwer, A Rajanuwong, W Chierakul, GE Griffin, RA Larsen, ... The Lancet 363 (9423), 1764-1767, 2004 | 611 | 2004 |
| Fungal infections in HIV/AIDS AH Limper, A Adenis, T Le, TS Harrison The Lancet Infectious Diseases 17 (11), e334-e343, 2017 | 598 | 2017 |
| Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy PR Williamson, JN Jarvis, AA Panackal, MC Fisher, SF Molloy, A Loyse, ... Nature Reviews Neurology 13 (1), 13-24, 2017 | 560 | 2017 |
| High-dose rifapentine with moxifloxacin for pulmonary tuberculosis A Jindani, TS Harrison, AJ Nunn, PPJ Phillips, GJ Churchyard, ... New England Journal of Medicine 371 (17), 1599-1608, 2014 | 549 | 2014 |
| Antifungal combinations for treatment of cryptococcal meningitis in Africa SF Molloy, C Kanyama, RS Heyderman, A Loyse, C Kouanfack, ... New England Journal of Medicine 378 (11), 1004-1017, 2018 | 468 | 2018 |
| Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes JN Jarvis, T Bicanic, A Loyse, D Namarika, A Jackson, JC Nussbaum, ... Clinical infectious diseases 58 (5), 736-745, 2014 | 445 | 2014 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 425* | 2022 |
| Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa JN Jarvis, SD Lawn, M Vogt, N Bangani, R Wood, TS Harrison Clinical infectious diseases 48 (7), 856-862, 2009 | 397 | 2009 |
| Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis JN Jarvis, A Percival, S Bauman, J Pelfrey, G Meintjes, GN Williams, ... Clinical infectious diseases 53 (10), 1019-1023, 2011 | 383 | 2011 |
| Superoxide Dismutase Influences the Virulence of Cryptococcus neoformans by Affecting Growth within Macrophages GM Cox, TS Harrison, HC McDade, CP Taborda, G Heinrich, ... Infection and immunity 71 (1), 173-180, 2003 | 366 | 2003 |
| Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or … T Bicanic, G Meintjes, R Wood, M Hayes, K Rebe, LG Bekker, T Harrison Clinical infectious diseases 45 (1), 76-80, 2007 | 350 | 2007 |
| Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial JN Jarvis, G Meintjes, K Rebe, GN Williams, T Bicanic, A Williams, ... Aids 26 (9), 1105-1113, 2012 | 348 | 2012 |
